The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Drug Updates: Efficacy & Safety of Guselkumab, Plus FX006 for Knee OA

Rheumatology Drug Updates: Efficacy & Safety of Guselkumab, Plus FX006 for Knee OA

February 16, 2017 • By Kelly April Tyrrell

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Image Credit: ajt/shutterstock.com

Image Credit: ajt/shutterstock.com

Guselkumab Improves Active Psoriatic Arthritis

New research has revealed that patients with active psoriatic arthritis (PsA) and ≥3% body area of plaque psoriasis benefit from treatment with a human monoclonal antibody known as guselkumab (GUS). GUS is specific for the p19 subunit of interleukin 23 (IL-23). Patients in the Phase 2 clinical trial experienced significant improvement in joint symptoms, physical function, psoriasis, enthesitis, dactylitis and quality of life. Specifically, more than half (58%) of the patients treated with GUS experienced at least a 20% improvement in ACR signs and symptoms of disease (ACR20) at Week 24 compared with 18.4% of placebo-treated patients—the study’s primary endpoint (P<0.001).1

You Might Also Like
  • Rheumatology Drug Updates: Efficacy Studied Following Accelerated Drug Approvals; Plus Secukinumab Meets Benchmark for Psoriasis
  • Guselkumab Improves Active Psoriatic Arthritis
  • Rheumatology Drug Updates: Hip Fracture Rates After Bisphosphonate Drug Holidays, Plus More on Golimumab, Ustekinumab
Explore This Issue
February 2017
Also By This Author
  • Does MRI Differentiate Osteoarthritis and Meniscal Tear in Knee Pain?

“It is encouraging to see how well patients responded to guselkumab with respect to improvements in signs and symptoms of psoriatic arthritis as early as Week 4 and to see the improvements in health-related quality of life outcomes, such as measures of physical and mental health,” says senior author Atul Deodhar, MD, a rheumatologist at Oregon Health & Science University in Portland, in an email to The Rheumatologist.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Participants in the double-blind, placebo-controlled multicenter study received standard-of-care therapy for PsA, including tumor necrosis factor alpha (TNFα) inhibitors. Despite standard treatment, the participants had at least 3% of their body surface area covered with plaques. The investigators randomized patients (2:1) to receive either 100 mg GUS subcutaneously or placebo at Weeks 0, 4 and every eight weeks thereafter through Week 44. Only four placebo-treated patients (8.2%) and nine GUS-treated patients (9.0%) had previously received TNFα inhibitors.

If patients from either group had less than a 5% improvement from baseline in both tender joint counts and swollen joints at Week 16, they were given the option of early escape to open-label ustekinumab. At Week 24, the remaining placebo patients crossed over to receive 100 mg GUS subcutaneously, given at Week 28 and every eight weeks thereafter through Week 44. The protocol was similar to that used with the initial randomization group.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“We learn something new with each of the studies using targeted biologic therapies,” explains Dr. Deodhar. “We were already aware that therapies that target IL-12 + IL-23 [ustekinumab] and those that target IL-17A were effective in treating psoriatic arthritis, but we did not know if specifically targeting IL-23 would demonstrate the same (or better) efficacy in the signs and symptoms of arthritis, enthesitis and dactylitis. Guselkumab is the first biologic therapy that specifically targets IL-23 that has been studied in PsA.” The results confirm that IL-23 plays a key role in the immunopathogenesis of psoriatic arthritis.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, DMARDs & Immunosuppressives, Drug Updates Tagged With: Approval, clinical trial, drug, FDA, FX006, guselkumab, knee, Medication, Osteoarthritis, outcome, patient care, plaque psoriasis, psoriatic arthritis, Research, rheumatology, Safety, TreatmentIssue: February 2017

You Might Also Like:
  • Rheumatology Drug Updates: Efficacy Studied Following Accelerated Drug Approvals; Plus Secukinumab Meets Benchmark for Psoriasis
  • Guselkumab Improves Active Psoriatic Arthritis
  • Rheumatology Drug Updates: Hip Fracture Rates After Bisphosphonate Drug Holidays, Plus More on Golimumab, Ustekinumab
  • Rheumatology Drug Updates: Giant Cell Arteritis Relapse Possible if Tocilizumab Discontinued; Plus Updates on Rituximab, Etanercept

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.